Collaboration Arrangements - Additional Information (Detail)						1 Months Ended		3 Months Ended		12 Months Ended
	Dec. 30, 2016 USD ($)	Nov. 09, 2016 USD ($)	Sep. 30, 2016 USD ($)	Apr. 04, 2016	Feb. 10, 2016 USD ($)	Jan. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2017 USD ($) Milestone	Dec. 31, 2016 USD ($) Milestone	Dec. 31, 2015 USD ($)	Sep. 23, 2014 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration										$ 250,000	$ 171,965,000
Secured loan facility, amount borrowed										19,429,000
Interest incurred through borrowings under Sanofi Loan Facility											4,478,000	$ 1,652,000
Gain on extinguishment of debt										(1,611,000)	72,024,000	(1,049,000)
Insulin Put
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration							$ 10,200,000
Sanofi-Aventis Deutschland GmbH | Put Option
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payment for insulin put option						$ 30,600,000					30,600,000
Aventisub LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Outstanding loan balance forgiven		$ 72,000,000
Receptor
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Nonrefundable payments										400,000
Nonrefundable option exercise and license fee	$ 1,000,000
Reduction in research and development expense										400,000
Net revenue from collaboration										300,000
Deferred revenue - nonrefundable license fee										$ 1,000,000
Deferred revenue recognition period										4 years
License and Collaboration Agreement with Sanofi
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Profits and losses sharing percentage										35.00%
Termination date				Apr. 04, 2016
Maximum secured loan facility													$ 175,000,000
Senior notes, effective interest rate													8.50%
Gain on extinguishment of debt		$ 500,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration								$ 10,200,000	$ 161,800,000		$ 172,000,000
Deferred revenue - nonrefundable license fee										$ 150,000,000
Profits and losses sharing percentage										65.00%
Number of milestone | Milestone										2	2
Milestone receivable										$ 25,000,000
Deferred cost												13,500,000
Secured loan facility, amount borrowed					$ 17,900,000							44,500,000
Secured loan facility, amount owed			$ 71,200,000						$ 71,200,000
Interest incurred through borrowings under Sanofi Loan Facility			$ 5,800,000
Gain on extinguishment of debt								$ 72,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Operating loss Sharing
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration											$ (64,900,000)
Company's total portion of loss sharing												57,700,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | AFREZZA product sales
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration											17,500,000
Deferred revenue - nonrefundable license fee												$ 17,500,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Up Front Payment [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration											150,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment One
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration											25,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment Two
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration											25,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Insulin Put
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration											$ 19,400,000